Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most commonly prescribed drugs in the world. NSAID-induced lower gastrointestinal (GI) complications are increasing while upper GI complications are decreasing. Lower GI events accounted for 40% of all serious GI events in patients on NSAIDs. Capsule endoscopy and device assisted enteroscopy are available for detection of small intestinal lesions. Capsule endoscopy studies have demonstrated that NSAIDs use in healthy volunteers raised the incidence (55% to 75%) of intestinal damage. It appears that selective cyclooxygenase-2 inhibitors (coxibs) improved upper and lower GI safety based on results of clinical trials. Selective coxibs are still capable of triggering GI adverse events and cardiovascular toxicity issues were the main focus of concerns. Unfortunately, definite strategies are not available to prevent or heal NSAID-induced intestinal injuries. Thus, there is still a strong clinical need for effective drugs with improved safety profiles than the existing NSAIDs.
INTRODUCTION
Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most commonly prescribed drugs in the world for their analgesic and anti-inflammatory properties. However, NSAID has limitation in prescribing because of gastrointestinal (GI) toxicity. Recently, NSAID-induced enteropathy has gained much attention due to the introduction of new emerging diagnostic modalities, capsule endoscopy (CE) and device assisted enteroscopy as well as due to the increased use of aspirin and NSAIDs. Recent CE studies have demonstrated NSAID use in healthy volunteers raised the incidence (55% to 75%) of intestinal damage. [1] [2] [3] [4] [5] [6] NSAID-induced enteropathy has been under-examined or even ignored in clinical situation before the times of CE.
Previous attention or studies have focused primarily on upper GI events but recent researches have shifted to the small bowel and colon during chronic NSAID use. Proton Clin Endosc 2012;45: [138] [139] [140] [141] [142] [143] [144] pump inhibitor (PPI) can't protect NSAID-induced intestinal injuries below Treitz ligament while PPI is very helpful to reduce NSAID-induced gastroduodenal damages. 7 Until now, no medications are available yet to prevent or heal NSAIDinduced intestinal injuries. It is important to extend the understanding about small bowel and colonic injuries associated with NSAID because all clinician, especially gastroenterologists, should have thorough knowledge of the GI toxicity of NSAIDs.
EPIDEMIOLOGY
It has been known that lower GI events accounted for onethird of all clinically relevant GI events. NSAID-induced lower GI complications (perforation, bleeding, or obstruction) are increasing while upper GI complications are decreasing. 7 In fact, the ratio of upper/lower was 4.1 in 1996 and it has decreased to only 1.4 in 2005. 7, 8 Current evidences suggest that NSAIDs increase the risk of lower GI bleeding and perforation to a similar extent to that seen in the upper GI tract. 9 Posthoc analysis of a large-scale clinical outcome trial showed that lower GI events accounted for 40% of all serious GI events in patients on NSAIDs. 10 There were notable CE studies in short-term NSAID users as well as chronic NSAID users. Goldstein et al. 5 reported that small bowel mucosal breaks were induced in 55% of healthy
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Yun Jeong Lim 1 and Chang-Hun Yang volunteers who had taken naproxen for 2 weeks. Maiden et al. 4 reported that 2-week ingestion of slow release diclofenac resulted in macroscopic injury to the small intestine in 68% to 75% of healthy volunteers. Graham et al. 3 performed CEs in arthritic patients who had been using NSAIDs for at least 3 months and reported as high as 71% for the incidence of small intestinal mucosal injury after chronic NSAID administration. The Japanese Study Group for Double-Balloon Endoscopy reported that NSAID-induced enteropathy occurred in half of the patients taking NSAIDs based on the registry of a 2-year period.
11 CE and double-balloon enteroscopy (DBE) findings suggest that the small intestinal mucosa is very sensitive to NSAID-induced injuries (Table 1) .
PATHOPHYSIOLOGY
The pathogenesis of NSAID-induced enteropathy is distinct from that of NSAID-induced gastropathy. Unlike stomach, NSAID-induced lower GI injuries are not caused by suppression of prostaglandin synthesis due to inhibition of cyclooxygenase (COX) activity 12, 13 but, most of the time, by gram negative bacteria and bile. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Bjarnason et al. 15 proposed a "three hit" hypothesis. First, NSAIDs solubilize lipids of phospholipids on the mucosal surface, so the epithelial mitochondria are directly damaged. Second, the mitochondrial damage depletes intercellular energy and leads to calcium efflux and to induction of free radicals, a disruption of intercellular junctions occurs, and mucosal permeability increases in the small intestinal mucosa. Third, the mucosal barrier becomes weakened, so bile acid, proteolytic enzymes, intestinal bacteria, or toxins can easily penetrate into the epithelial cells, resulting in mucosal injury. NSAID-induced small intestinal injuries augment through the enterohepatic circulation of the NSAID (Fig. 1 ).
14 NSAIDs with no enterohepatic circulation did not cause significant intestinal damage in animal models.
14
CLINICAL PICTURES
NSAIDs affect the entire GI system and can often cause various abdominal symptoms such as epigastric pain, nausea, indigestion, constipation, and abdominal distension. 13 Multiple ulcers and erosions are common NSAID-induced small intestinal lesions.
14 Ulceration often occurs in the GI tract without symptoms because of analgesic effect of NSAIDs. Aspirin itself can also cause stomach and duodenal ulcers, but it is generally believed that aspirin does not usually cause small bowel damage according to intestinal permeability and fecal inflammatory marker studies and aspirin does not have enterohepatic circulation.
14 Enteric coated aspirin was originally designed to decrease adverse effects on the stomach, but the use of enteric coated aspirin may have shifted the damage to the distal small bowel. Low dose aspirin is not safe, and chronic low dose aspirin use induced small bowel enteropathy that has many striking similarities with NSAID-induced enteropathy. 23 NSAIDs were found to induce obscure overt GI bleeding which manifests as hematochezia or melena, or occult obscure GI bleeding, as positive guaiac fecal occult blood test or anemia of unknown etiology. 24 NSAID-induced enteropathy is one of the most common causes of obscure GI bleeding. 24 NSAID-induced enteropathy might be suspected strongly in patients with obscure GI bleeding and recent history of taking aspirin or NSAIDs. CE sensitively detects NSAID-induced small intestinal injuries such as red spot, erosion, and ulcer, while NSAID-induced small intestinal injuries are not specific in endoscopic findings and NSAID-induced ulcer is hard to differentiate from other causes of ulcer such as Crohn' s disease. NSAID-induced small intestinal bleeding can be effectively controlled by a device assisted enteroscopy (Fig. 2) . Concentric diaphragmatic stricture is thought to be the pathognomonic symptom of NSAID injury. 25 Clinical presentation of diaphragm disease is nonspecific and may be presented with obstructive symptoms. It develops from scarring reaction secondary to ulcerative injury during long-term NSAID use. The histological features of the diaphragm-like stricture include fibrosis in the submucosa and thickening of the muscularis mucosa. 26 Since the muscularis propria layer is intact, the risk of intestinal perforation is low with endoscopic balloon dilation, which is why it is a preferred treatment modality than surgical intervention. 27 Capsule can be retrieved successfully by enteroscopy in case of the capsule entrapment.
In randomized trials in patients with rheumatoid or osteoarthritis, diverticulitis and diverticular bleeding are the most common etiologies of NSAID-induced lower GI injuries, accounting for 30% to 50% of all serious GI events associated with NSAIDs. 28 Case control studies have shown a significantly higher prevalence of NSAID use with complications of diverticular diseases (diverticulitis and bleeding) compared to controls -their risk estimates varied widely with odds ratios ranging from 1.8 to 16.
7 Regular use of aspirin or NSAIDs was associated with increased risks of diverticulitis and diverticular bleeding.
7,29
DIAGNOSIS
NSAIDs can induce a variety of abnormalities including ulcerations, perforations, bleeding, and diaphragm-like strictures in the human small intestine. 7 Difficulties in accessing the entire small intestine prevented comprehensive evaluation of the extent and localization of NSAID-induced small intestinal injury, however. Thus, prior to the advent of CE and small bowel enteroscopy, most studies had to rely on surrogate markers such as urinary excretion of chromium-51-labeled ethylenediaminetetraacetic acid, which shows intestinal permeability and fecal level of calprotectin, a proposed marker of intestinal inflammation. 30, 31 Calprotectin is a 36 kDa calcium-binding protein constituting up to 60% of the cytosolic proteins in neutrophil granulocytes and plays an important role in inflammatory processes. 32 It is excreted in feces and remains stable against bacterial degradation. 33 The presence of calprotectin in feces is a consequence of neutrophils' migration into the GI tissue. 33 But now, with CE, we can easily locate the site of injury and evaluate the incidence rates and types of injuries. Presently, CE and DBE are available for direct detection of small intestinal lesions. Endoscopic findings of NSAID-induced enteropathy include reddish erosion, multiple sharply demarcated ulcer and concentric stenosis. Multiple discrete ulcers are the most frequent finding. NSAID-induced small intestinal lesions on CE include denuded areas, erosions and ulcers (Fig. 3) . A denuded area is defined as a reddened area without villi. 4 Maiden et al. 4 classified CE findings into five categories: reddened folds, denuded area, red spot, mucosal break, and blood. Graham et al. 3 divided CE findings into red spots, small erosions, large erosions, and ulcers, and they found mucosal lesions in 13 out of 21 patients (62%) with chronic NSAID use. Small lesions such as erosions and red spots are detected more often by CE than DBE. 
TREATMENT AND FUTURE DIRECTION
Previous efforts have focused primarily on GI events in the upper GI tract, but recently, efforts have been made to reduce NSAID-induced small bowel and colon injuries including mucosal damage, ulceration, overt bleeding, obstruction/perforation, protein-loss and occult blood loss (with an associated decrease in hemoglobin).
Fujimori et al. 34 demonstrated the benefit of treatment with misoprostol in a small pilot study in which small intestinal damage was assessed by CE. Misoprostol co-therapy reduced the incidence of small intestinal lesions induced by a 2-week administration of diclofenac sodium in healthy subjects. Watanabe et al. 35 examined therapeutic effect of misoprostol against aspirin induced injury. Their subjects were gastric ulcer patients who were orally taking low dose, enteric coated aspirin. They were treated with PPI for 8 weeks, but all patients had redness and erosions in the small intestine on CE at 8 weeks. When misoprostol was administered instead of PPI for additional 8 weeks, small intestinal lesions were improved on the follow-up CE. Misoprostol appeared to be capable of healing aspirin induced small bowel injury.
Selective COX-2 inhibitors (coxibs) were introduced to the marketplace in the mid-1990s with a promise of improved GI safety. Goldstein et al. 5 reported that 2-week regimen with celecoxib, a selective coxib, caused less small intestinal injury than a regimen using naproxen. Selective coxibs were believed to be less injurious than nonselective NSAIDs in the small bowel as well as in the stomach, but Maiden et al. 1 found no difference in the incidence of small intestinal injury between chronic users of nonselective NSAIDs and selective coxibs. Selective coxibs may not provide complete protection against GI toxicity. Selective coxibs are selective, but not exclusive, and thus have some COX-1 inhibitory activity. Further studies with large samples are needed to decide whether or not selective coxibs can entirely control GI toxicity.
Niwa et al. 36 conducted a prospective, double-blind study of CE using a mucosal protective agent, rebamipide, in healthy subjects. It was found that subjects who received placebo had significantly more mucosal injuries in the small intestine compared to those who received rebamipide. Mucosal protecting agents such as teprenone, rebamipide, and irsogladine showed protective effect against NSAID-induced small intestinal injuries according to animal experiments using rats; more specifically, the increase in iNOS mRNA expression and myeloperoxidase activity due to indomethacin was inhibited by pretreatment with these mucosal protecting agents. 24 Several strategies have been tried to develop new compounds with improved GI tolerability. Several companies are developing drugs that co-release an NSAID (naproxen, aspirin, or ibuprofen) and a PPI (omeprazole, esomeprazole, or lansoprazole); these compounds are already filed with the FDA or in very late stages of development. 37 These compounds have been shown to reduce the incidence of NSAID-induced gastropathy but not enteropathy.
Significant part of NSAIDs' GI injury mechanism is related to their topical irritancy. PLx Pharma Inc. (Houston, TX, USA) has taken a strategy to reduce the topical irritant property of NSAIDs and has developed NSAIDs that are associated with phosphatidylcholine. 38 Extensive animal works have demonstrated that phosphatidylcholine-NSAIDs are less likely to damage the GI epithelium in rodents, and produce less severe mucosal injury while retaining the anti-inflammatory effects of the parent NSAID. In a randomized, double-blind, endoscopy study, ibuprofen preassociated with phosphatidylcholine showed superior GI toxicity than an equivalent dose of ibuprofen in the subgroup of patients older than 55 years. 39 The discovery that nitric oxide (NO) is a potent gastroprotective substance that modulates many aspects of GI mucosal defense led to the development of NO releasing NSAIDs, which are also referred to as COX-inhibiting NO donors. 40 The compound has shown improved GI tolerability in some but not all clinical trials. Like NO, hydrogen sulfide (H2S) has been shown to exert protective effects in the GI tract and to accelerate the healing of preexisting ulcers. H2S-releasing NSAIDs, derivatives of naproxen, diclofenac, and indomethacin have been reported. [41] [42] [43] Phosphatidylcholine associated NSAIDs as well as NO-and H2S-releasing NSAIDs are under extensive preclinical testing for their influence on NSAIDinduced enteropathy. Further studies are warranted to develop promising new NSAID with total GI (upper and lower GI tracts) tolerability and without cardiovascular toxicity.
CONCLUSIONS
NSAIDs are one of the most commonly prescribed drugs in the world for analgesic and anti-inflammatory properties. Previous studies have focused primarily on upper GI events; but recently, NSAID-induced enteropathy has gained much attention due to the introduction of new emerging diagnostic modalities, CE and device assisted enteroscopy. Lower GI events accounted for 40% of all serious GI events in patients taking NSAIDs.
14 CE studies have demonstrated NSAID use in healthy volunteers raised the incidence (55% to 75%) of intestinal damage. [1] [2] [3] [4] [5] [6] Unfortunately, however, PPI can't protect NSAID-induced intestinal injuries below Treitz ligament; Selective coxibs improved upper and lower GI safety according to results of clinical trials, 23 but coxibs are still capable of triggering GI adverse events and are still concerned to be associated with cardiovascular toxicity issues. Thus, there is still a strong clinical need for effective anti-inflammatory drugs with superior safety profiles than the existing NSAIDs.
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